Open AccessARV‐based HIV prevention for women – where we are in 2014
Author(s) -
Mastro Timothy D,
Sista Nirupama,
AbdoolKarim Quarraisha
Publication year - 2014
Publication title -
journal of the international aids society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.724
H-Index - 62
ISSN - 1758-2652
DOI - 10.7448/ias.17.3.19154
Subject(s) - medicine , human immunodeficiency virus (hiv) , pre exposure prophylaxis , virology , family medicine , men who have sex with men , syphilis
Women continue to be at special risk for HIV acquisition due to a complex mix of biological, behavioural, structural, cultural and social factors, with unacceptable rates of new infection. Scientific advances over the past decade have highlighted the use of antiretroviral (ARV) drugs as pre‐exposure prophylaxis (PrEP) to prevent HIV acquisition (sexually, parenterally and vertically) and ARV treatment (ART) for HIV‐positive patients to prevent onward transmission (treatment as prevention – TasP). This paper reviews the evidence base for PrEP and TasP, describes new products in development and the need to translate research findings into programmes with impact at the population level.